RESUMEN
BACKGROUND: Small intestinal neuroendocrine neoplasms (SI-NEN) are rare, and only about 40% of patients are diagnosed without distant metastases. Aim of the study was to identify prognostic factors in patients with potentially curative resected locoregional SI-NEN. METHODS: Patients with curative resected locoregional SI-NEN (ENETS stages I-III) were retrieved from a prospective data base. Demographic, surgical and pathological data of patients with and without disease recurrence were retrospectively analyzed using univariate and multivariate analysis. RESULTS: In a 20-year period, 65 of 203 (32%) patients with SI-NEN were operated for stages I-III disease. Thirty-eight (58.5%) patients were men, and the median age at surgery was 59 (range 37-87) years. After median follow-up of 65 months, 14 patients experienced disease relapse median 28.5 (range 6-122) months after initial surgery, of which 2 died due to their disease. Multivariate analysis revealed age ≥ 60 years (HR = 6.41, 95% CI 1.38-29.67, p = 0.017), tumor size ≥ 2 cm (HR = 26.54, 95% CI 4.46-157.62, p < 0.001), lymph node ratio > 0.5 (HR 7.18, 95% CI 1.74-29.74, p = 0.007) and multifocal tumor growth (HR = 6.98, 95% CI 1.66-29.39, p = 0.008) as independent negative prognostic factors and right hemicolectomy compared to segmental small bowel resection (HR = 0.04, 95% CI 0.01-0.24, p < 0.001) as independent protector against recurrence. CONCLUSION: Patients with locoregional SI-NEN with an age ≥ 60 years, tumor size ≥ 2 cm, lymph node ratio > 0.5 and multiple small bowel tumor foci have an increased risk for recurrence and might benefit from adjuvant treatment. In contrast, right hemicolectomy of ileal SI-NEN seems to reduce the risk of recurrence.
Asunto(s)
Intestino Delgado , Recurrencia Local de Neoplasia , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Intestino Delgado/cirugía , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/cirugía , Pronóstico , Estudios Prospectivos , Estudios RetrospectivosRESUMEN
Partially acetylated chitosan oligosaccharides (paCOS), consisting of ß-1,4-linked N-acetyl-d-glucosamine and d-glucosamine units, possess diverse bioactivities that can be used for applications in, e.g., biomedicine, agriculture, and pharmaceutics. Establishing structure-function relationships and revealing modes of action requires the availability of structurally defined paCOS that can best be produced using chitin- and chitosan-modifying enzymes, such as chitinases and chitosanases, with known and defined subsite specificities. To enlarge the spectrum of such enzymes and, consequently, defined paCOS available, we have developed a two-step, microtiter plate-based high-throughput screening assay that allows quantification of the activity and subsite specificities of chitosan hydrolases. In a first step, the activities of the enzymes are quantified using a reducing end assay, and enzymes with sufficient activity are then screened for their subsite specificities using mass spectrometric analysis of their products when acting on well-defined chitosan polymers as substrates. The rapid UHPLC-ELSD-ESI-MS2 method does not require labeling steps or addition of standards, and the principal component analysis of the fragment ion intensities of just two isomeric oligomer groups, GlcNAc1GlcN3 and GlcNAc2GlcN2, sufficed to identify, in a directed evolution, the site-saturation mutagenesis library of Bacillus sp. MN chitosanase consisting of 167 muteins, enzymes that significantly differed in their subsite specificities from the wildtype enzyme. Detailed analyses of a few selected muteins proved that the screening method is efficient and accurate in predicting altered subsite specificities.
Asunto(s)
Quitinasas/metabolismo , Cromatografía Líquida de Alta Presión , Pruebas de Enzimas/métodos , Glicósido Hidrolasas/metabolismo , Espectrometría de Masas , Bacillus/enzimología , Especificidad por SustratoRESUMEN
PURPOSE: To evaluate albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) grades in predicting overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This single-center retrospective study included 180 high-risk patients (142 men, 59 y ± 9) between April 2007 and January 2015. Patients were considered high-risk based on laboratory abnormalities before the procedure (bilirubin > 2.0 mg/dL, albumin < 3.5 mg/dL, platelet count < 60,000/mL, creatinine > 1.2 mg/dL); presence of ascites, encephalopathy, portal vein thrombus, or transjugular intrahepatic portosystemic shunt; or Model for End-Stage Liver Disease score > 15. Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades. Overall survival was stratified by ALBI and PALBI grades with substratification by Child-Pugh class (CPC) and Barcelona Liver Clinic Cancer (BCLC) stage using Kaplan-Meier analysis. C-index was used to determine discriminatory ability and survival prediction accuracy. RESULTS: Median survival for 79 ALBI grade 2 patients and 101 ALBI grade 3 patients was 20.3 and 10.7 months, respectively (P < .0001). Median survival for 30 PALBI grade 2 and 144 PALBI grade 3 patients was 20.3 and 12.9 months, respectively (P = .0667). Substratification yielded distinct ALBI grade survival curves for CPC B (P = .0022, C-index 0.892), BCLC A (P = .0308, C-index 0.887), and BCLC C (P = .0287, C-index 0.839). PALBI grade demonstrated distinct survival curves for BCLC A (P = 0.0229, C-index 0.869). CPC yielded distinct survival curves for the entire cohort (P = .0019) but not when substratified by BCLC stage (all P > .05). CONCLUSIONS: ALBI and PALBI grades are accurate survival metrics in high-risk patients undergoing conventional transarterial chemoembolization for HCC. Use of these scores allows for more refined survival stratification within CPC and BCLC stage.